BMI1 and neoplasm: Furthermore, pharmacological or genetic inhibition of BMI1 not only aids in eliminating BMI1+CSCs but also potentiates the effects of PD-1 blockade by activating the intrinsic immunity of tumor cells, thereby suppressing metastatic tumor growth and reducing the risk of tumor recurrence (183).